{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-048593","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2024-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.147284+00:00","generated_at":"2026-05-29T21:53:30.969984+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"C4 Therapeutics appoints Steve Hoerter, former Deciphera CEO, to board of directors","bullets":["Steven L. Hoerter appointed as Class II director effective November 19, 2024; serves until 2025 annual meeting.","Hoerter has over 30 years of oncology leadership; was CEO of Deciphera (acquired by ONO for $2.4B).","Granted 65,000 stock options under 2020 Plan; vests 1/3 on first anniversary, remainder quarterly over 2 years.","Board determined Hoerter independent per Nasdaq standards; brings commercialization expertise to guide pipeline.","Hoerter also serves on ORIC Pharmaceuticals board; previously led QINLOCK and TIBSOVO launches."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-048593","json":"https://secwatch.observer/filing/0001628280-24-048593.json","markdown":"https://secwatch.observer/filing/0001628280-24-048593.md","text":"https://secwatch.observer/filing/0001628280-24-048593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024048593/0001628280-24-048593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024048593/cccc-20241120.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T21:53:30.969984+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf305a6ce3","claim":"Steven L. Hoerter was appointed as Director at C4 Therapeutics, Inc..","evidence_excerpt":"On November 19 , 2024 , the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Steven L. Hoerter as a director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024048593/0001628280-24-048593-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}